Expression of Peroxiredoxin 1 and 4 Promotes Human Lung Cancer Malignancy by Jiang, Hong et al.
University of Kentucky
UKnowledge
Toxicology and Cancer Biology Faculty
Publications Toxicology and Cancer Biology
9-15-2014
Expression of Peroxiredoxin 1 and 4 Promotes
Human Lung Cancer Malignancy
Hong Jiang
University of Kentucky, hong.jiang@uky.edu
Lisha Wu
University of Kentucky
Murli Mishra
University of Kentucky, murli.mishra@uky.edu
Hedy A. Chawsheen
University of Kentucky, chawsheen@uky.edu
Qiou Wei
University of Kentucky, qiou.wei@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/toxicology_facpub
Part of the Medical Toxicology Commons
This Article is brought to you for free and open access by the Toxicology and Cancer Biology at UKnowledge. It has been accepted for inclusion in
Toxicology and Cancer Biology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Jiang, Hong; Wu, Lisha; Mishra, Murli; Chawsheen, Hedy A.; and Wei, Qiou, "Expression of Peroxiredoxin 1 and 4 Promotes Human
Lung Cancer Malignancy" (2014). Toxicology and Cancer Biology Faculty Publications. 38.
https://uknowledge.uky.edu/toxicology_facpub/38
Expression of Peroxiredoxin 1 and 4 Promotes Human Lung Cancer Malignancy
Notes/Citation Information
Published in American Journal of Cancer Research, v. 4, no. 5, p. 445-460.
AJCR Copyright © 2014
This article is available under the “Creative Commons Attribution Noncommercial License”, enabling the
unrestricted non-commercial use, distribution, and reproduction of the published article in any medium,
provided that the original work is properly cited.
This article is available at UKnowledge: https://uknowledge.uky.edu/toxicology_facpub/38
Am J Cancer Res 2014;4(5):445-460
www.ajcr.us /ISSN:2156-6976/ajcr0001380
Original Article 
Expression of peroxiredoxin 1 and 4 promotes human 
lung cancer malignancy 
Hong Jiang1,2, Lisha Wu1,2, Murli Mishra1,2, Hedy A Chawsheen1,2, Qiou Wei1,2
1Graduate Center for Toxicology, 2The Markey Cancer Center, University of Kentucky College of Medicine, Lexing-
ton, KY 40536, USA 
Received July 10, 2014; Accepted August 12, 2014; Epub September 6, 2014; Published September 15, 2014
Abstract: Members of the Peroxiredoxin (Prx) family are major cellular antioxidants that scavenge hydrogen perox-
ide and play essential roles in oxidative stress and cell signaling. 2-Cys Prxs, including Prx1, 2, 3 and 4, have been 
indicated in multiple oncogenic signaling pathways and thus may contribute to various processes of cancer develop-
ment. The significance of 2-Cys Prxs in lung cancer development and their biological function in signal transduction 
have not been fully investigated. In this study we analyzed the expression of 2-Cys Prxs in lung cancer, and examined 
their levels of expression in a variety of cell lines established from human lung normal or cancer tissues. We found 
that 2-Cys Prxs, in particular, Prx1 and Prx4, were preferentially expressed in cell lines derived from human lung 
cancer. Through isoform specific knockdown of individual Prx, we demonstrated that Prx1 and Prx4 (but not Prx3) 
were required for human lung cancer A549 cells to form soft agar colony and to invade through matrigel in culture. 
Knockdown of Prx1 or Prx4 significantly reduced the activation of c-Jun and repressed the AP-1 mediated promoter 
activity. In mouse xenograft models, knockdown of Prx4 in A549 cells reduced subcutaneous tumor growth and 
blocked metastasis formation initiated through tail vein injection. Moreover, overexpression of Prx1 or Prx4 further 
enhanced the malignancy of A549 cells both in culture and in mouse xenografts in vivo. These data provide an in-
depth understanding of the contribution of Prx1 and Prx4 to lung cancer development and are of importance for 
future development of therapeutic methods that targeting 2-Cys Prxs.
Keywords: Peroxiredoxin, lung cancer, tumor invasion and metastasis, cell signaling
Introduction 
Peroxiredoxins (Prxs), or thioredoxin-dependent 
peroxidases, are originally discovered as cellu-
lar antioxidants with peroxidase activity. They 
scavenge H2O2 to reduce oxidative stress and 
to protect the inactivation of multiple cellular 
enzymes including proteins such as glutamine 
synthetase [1]. There are six isoforms of Prxs in 
mammals. Based on the number and position 
of Cysteine residues involved in the peroxidase 
reaction, they are classified into three sub-
groups, i.e., 2-Cys, atypical 2-Cys and 1-Cys 
Prxs. The 2-Cys Prxs, including Prx1, 2, 3 and 4, 
are the predominant Prxs in mammalian cells 
[2]. Most Prxs are considered as ubiquitously 
expressed in various tissues and organs,  and 
they varies in their subcellular locations, such 
as cytoplasm (Prx1, 2 and 6), nucleus (Prx1), 
mitochondria (Prx3, 5 and 6), peroxisomes 
(Prx5), endoplasmic reticulum (Prx4), or even 
secreted into extracellular matrix in certain 
type of cells (Prx4) [3, 4]. Due to these varia-
tions and their structure characteristics, mem-
bers of the Prx family may have non-redundant, 
distinct intracellular functions. For example, 
expression and activation of Prx1 are required 
for the growth and proliferation of human mam-
mary epithelial cells [5]. Prx1 also interacts with 
oncogenic protein c-Abl to inhibit its tyrosine 
kinase activity [6]. Prx 2 is a negative regulator 
of platelet-derived growth factor (PDGF) recep-
tor signaling, and depletion of Prx2 results in 
increased cell proliferation and migration in 
response to PDGF in mouse fibroblasts and 
human muscle cells [7]. Prx2 can also function 
as a negative regulator of NF-κB signaling in 
mouse fibroblasts [8]. Prx3 is a target of c-Myc 
activation in rat fibroblasts and is required for 
Myc-mediated cell proliferation and transfor-
mation [9]. Prx4 also acts as a negative regula-
tor of NF-κB activation in HeLa cells [10]. These 
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studies reveal that, in addition to be scaven-
gers and mediators of hydrogen peroxide sig-
naling, members of the Prx family involve not 
only cellular response to oxidative stress but 
also various physiological or pathological pro-
cesses. Therefore, understanding the contribu-
tion and molecular basis of Prxs in cell signal 
transduction may be of important value for the 
development of novel strategies to prevent or 
treat human disease. 
Previous studies report that certain Prxs are 
aberrantly activated and expressed in a variety 
of human cancer, including breast cancer (Prx 
1, 2 and 3) [11], lung cancer (Prx1, 3 and 4) [12, 
13], bladder cancer (Prx1 and 6) [14], thyroid 
cancer (Prx1) [15] and oral squamous cell carci-
noma (Prx1) [16]. However, the role of Prxs in 
tumorigenesis and cancer progression has not 
been fully investigated and understood. For 
example, the role of Prx1 in human cancer is 
still controversial in that it can either function 
as a tumor suppressor or a pro-oncogenic fac-
tor, depending on the cellular context. There 
are several lines of evidence support that Prx1 
functions as a tumor suppressor. Firstly, elevat-
ed expression of Prx1 in Myc-transformed fibro-
blasts significantly reduces anchorage-inde-
pendent colony formation and tumorigenesis in 
a mouse xenograft model [17].  Secondly, Prx1 
knockout cells are much more susceptible to 
Ras transformation [18]. Thirdly, genetic loss of 
Prx1 in mice leads to spontaneous tumor for-
mation in multiple organs [19]. On the other 
hand, the pro-oncogenic role of Prx1 in tumori-
genesis and cancer progression is also well 
documented in literature. For example, the lev-
els of Prx1 in specimens of bladder cancer 
have been found to be significantly higher than 
normal adjacent tissue, and the increased 
expression of Prx1 is associated with worse 
clinical staging, higher rate of recurrence and 
poor prognosis [14]. Expression of Prx1 in 
breast cancer facilitates cancer cell survival 
from oxidative stress induced cell death and 
promotes cancer cell malignancy [20, 21]. The 
pro-survival effect of Prxs may be attributed to 
its function as a molecular chaperone to 
enhance resistance to stress as demonstrated 
in yeast and various mammalian cells [22, 23]. 
The exact role of other 2-Cys Prxs in human 
cancer development is also not conclusive. 
Therefore, a systematic evaluation of Prxs may 
be critical for the understanding of their biologi-
cal significance. In particular, the study of 2-Cys 
Prxs should be accomplished under the specif-
ic context of certain types of human cancer. 
Lung cancer is the leading cause of cancer-
related mortality in USA and worldwide. Alth- 
ough significant progress has been made over 
the past decade in the early detection and com-
bined treatment of lung cancer, the five-year 
survival rate of patients with advanced lung 
cancer is less than 20% (cancer statistics, 
WHO). With more than fifty histological vari-
ants, lung cancer is extremely heterogeneous 
and adenocarcinoma accounts for more than 
40% of its overall incidence. In this study, we 
examined the expression of 2-Cys Prxs in 
human lung cancer and explored the functional 
significance of each isoform of 2-Cys Prxs 
under the context of lung adenocarcinoma. Our 
data shed light on the differential function of 
individual member of the Prx family in lung can-
cer development and we identified the unique 
contribution of Prx1 and Prx4 in lung cancer 
development and intracellular signal transduc-
tion. Our findings may provide novel insights for 
the understanding of human lung cancer 
pathogenesis.
Materials and methods
Cell lines 
HEK293T cells and all other cell lines were 
commercially obtained from NCI repository or 
ATCC. Three immortalized cell lines established 
from lung normal epithelium were used, includ-
ing BEAS-2B (immortalized by SV40 T antigen), 
NL20 (immortalized by SV40 T antigen) and 
Nuli-1 (immortalized by HPV-E6/7 and hTERT). 
Two cell lines established from lung small cell 
carcinoma were used, including NCI-H69 and 
NCI-H82 cells. Three cell lines established from 
lung squamous cell carcinoma were used, 
including NCI-H520 (from primary tumor), NCI-
H226 and SK-MES-1(from pleural effusion). 
Three cell lines established from lung adeno-
carcinoma were used, including A549 (from pri-
mary tumor), NCI-H2030 (from lymph node 
metastasis) and NCI-H2122 (from pleural effu-
sion). Cells were cultured in provider’s suggest-
ed culture medium in an atmosphere of 5% CO2 
at 37°C with 80~85% relative humidity. 
Cell lysis and western blotting
Cultured cells were lysed in RIPA lysis buffer in 
the presence of proteinase inhibitors. Proteins 
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were separated on a 4-12% gradient gel and 
transferred to PVDF membrane. Western blot 
was performed using standard protocol. 
Primary antibodies used include, rabbit anti-
Prx1, 2 and 4 (Abcam), mouse anti-β-actin 
(Sigma-Aldrich), mouse anti-Prx3, c-Jun, and 
c-Myc (Santa Cruz), phosphor-c-Jun (p-63 and 
p-73) (Cell Signaling). Western blotting was per-
formed following standard procedure. 
Lentiviral ShRNA knockdown of Prx and estab-
lishment of stable knockdown cell lines
Strictly controlled ShRNA-based knockdown 
experiments were designed and performed 
according to previous published suggestions 
[24]. All ShRNA constructs including MISSION® 
pLKO.1-puro control vector (vector control), MI- 
SSION® Non-Target shRNA (ShNT) and ShRNAs 
specifically targeting either Prx1 (ShPrx1), 3 
(ShPrx3), or 4 (ShPrx4) were commercially obt- 
ained (Sigma-Aldrich) and all sequences were 
confirmed by commercial sequencing. Lentiviral 
particles expressing ShRNAs were produced in 
HEK293T cells using the provider’s plasmid 
packaging system and Fugene 6 transfection 
reagent following suggested transfection and 
virus production procedures. The titer of virus-
containing medium was determined by measur-
ing the level of p24 using the ELISA and Lenti-X 
GoStix kits (Clontech). To establish stable kno- 
ckdown, A549 cells were infected with lentiviral 
particles at a multiplicity of infection (MOI) aro- 
und 10 in all experiments. Cells were mainta- 
ined in puromycin containing medium to estab-
lish stable cells. 
Cloning of human 2-Cys Prxs into lentiviral ex- 
pression vector and establishment of overex-
pressing stable cells
To clone human Prx1, 2, 3 and 4, the total 
mRNAs of cultured HEK293T cells were extract-
ed and purified following commercial kit proto-
col (Qiagen). Reverse transcriptase PCR 
(RT-PCR) was performed using gene specific 
primer and SuperScript™ reverse transcriptase 
kit (Invitrogen). The coding region of Prx gene 
was first cloned into the BamH I/Xho I sites of 
the pCDNA3.1-Myc vector to generate expres-
sion plasmid that encodes c-Myc tagged fusion 
protein. The coding sequences were confirmed 
by DNA sequencing and fusion protein expres-
sion was verified by western blot. The validated 
coding sequences of the fusion protein were 
then transferred into pLVX-IRES-Puro vector for 
expression in lentiviral vectors using restriction 
enzyme digestion and T4 DNA ligase. For lenti-
virus production, Fugene 6 and Clontech’s lenti-
viral packaging system were used to produce 
infectious particles that expressing pLVX-IRES-
Puro empty vector (vector control) or c-Myc 
tagged Prx. A549 cells were then infected and 
maintained in puromycin containing medium as 
described above for stable cell selection.
Colony formation in soft agar and transwell 
matrigel cell invasion assay
For colony formation experiment, cells were 
suspended in 0.3% agar and 15,000 cells/well 
were seeded into 6-well plate pre-coated with 
1.0 ml of 0.6% agar. Medium was changed 
every 5 days for four weeks. The number and 
size of colonies were examined and data were 
obtained by analyzing with Image J software. 
Transwell matrigel invasion assays using BD 
invasion chamber were performed following the 
manufacturer’s suggested protocol with 10% 
serum containing medium as chemo-attrac-
tants. Invaded cells were stained by Diff-
QuikTM staining and images were taken under 
microscope (X4). Numbers of invaded cells 
were counted using the Image J software. 
Proteome profiler human phospho-kinase ar-
ray 
The antibody based array kit, which is capable 
of simultaneously measuring the levels of 46 
phosphorylated proteins (all are kinase sub-
strates) in duplicates on the same membrane, 
was commercially obtained (R&D Systems). 
Cells were cultured in 100 mm2 dishes and 
starved for 24 hours, followed by stimulation 
with or without 10% serum-containing medium 
for 15 minutes. Cells were then harvested in 
RIPA lysis buffer and 700 μg of cell lysates were 
used for kinase array following the manufac-
turer’s suggested protocol. All array membra- 
nes were processed at the same time under 
the same conditions, and results were obtained 
by exposing membranes to a single X-ray film 
with exactly the same duration of exposure 
time. The intensity of each spot representing 
individual phosphorylated protein was deter-
mined using Image J software. The relative spot 
intensity was obtained by normalizing with the 
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intensity of the internal positive control on each 
membrane. 
The AP-1 luciferase reporter activity assay
 A549 cells cultured in 96-well plate were tran-
siently transfected with an AP-1 firefly lucifer-
ase reporter construct and a control renila 
luciferase construct using Lipofectamine 2000. 
Luciferase activities were measured at 48 ho- 
urs after transfection using a dual luciferase as- 
say kit (Promega) and a luminometer. Relative 
luciferase unit (RLU) was determined as the 
ratio of firefly luciferase to renila luciferase va- 
lue. 
Subcutaneous or tail-vein injection of A549 
cells into SCID mice
The protocol for mouse xenograft experiments 
was reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC). All 
animal procedures were conducted following 
the Policy on Humane Care and Use of Lab- 
oratory Animals, and Guidelines of the Animal 
Care and Laboratory Animal Welfare (NIH). A 
double-blind experimental design was applied 
to eliminate potential subjective bias on proto-
col execution and data collection. Briefly, sev- 
ere combined immunodeficiency (SCID) female 
mice at 5-week old were commercially obtained 
(NCI). Mice were exposed to food and water ad 
libitum and hosted in a 12/12 (hr/hr) light-dark 
cycle. At the age of 6-week, mice were random-
ly separated into six groups to receive either 
A549 ShNT, ShPrx4 or MycPrx4 cells. A total of 
5 × 105 cells/mouse (in 100 μl of PBS) were 
injected either subcutaneously or through tail-
vein. The growth of tumor in subcutaneous 
injection was measured with a calibre every 
other day, until the diameter at one dimension 
was equal or larger than 1.0 cm. Groups of 
mice injected with tumor cells through tail-vein 
were all euthanized at 8 weeks after injection 
due to the deterioration of health in the group 
receiving MycPrx4 cells. Primary tumors (sub-
cutaneous injection) and mouse lung (tail-vein 
injection) were fixed in 4% paraformaldehyde 
and stored in 70% ethanol, and proceeded with 
standard paraffin-embedding, sectioning, H&E 
staining and histopathological examination. 
Statistical analysis 
Quantitative data were presented as means ± 
standard deviation (
_
x  ± sd). Data were ana-
lyzed with indicated statistical methods using 
GraphPad Prism (Version 5.04). For calculation 
of the p value, parameters of two-tailed, 95% 
confidence interval were used for all analysis. A 
Figure 1. mRNA expression of 2-Cys Prxs in human lung normal and cancer tissues from published microarrays. 
Data were summarized using the Oncomine database (www.oncomine.com). A: Microarray results from Garber M.E., 
et al, PNAS USA 98:13784~9. Category and number of samples included: 0, normal lung (n = 6); 1, large cell lung 
carcinoma (n = 4); 2, lung adenocarcinoma (n = 42); 3, small cell lung carcinoma (n = 5); 4, squamous cell lung car-
cinoma (n = 16). B: Microarray results from Bhattacharjee A., et al, PNAS USA 98:13790~5. Category and number 
of samples included: 0, normal lung (n = 17); 1, lung adenocarcinoma (n = 139); 2, lung carcinoid tumor (n = 20); 
3, small cell lung carcinoma (n = 6); 4, squamous cell lung carcinoma (n = 21).
Peroxiredoxins in lung cancer
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p value of less than 0.05 is considered statisti-
cally significant. 
Results
Differential expression of Prxs in human lung 
cancer and cell lines
 To date there are no reports in the literature 
that simultaneously evaluate the transcript and 
protein levels of 2-Cys Prxs in human lung can-
cer. Therefore we first examined the published 
repository of gene expression profiling for Prxs 
using Oncomine database. By focusing on the 
human lung cancer microarray data, we identi-
fied and summarized the expression profiling of 
Prx1, 2, 3 and 4 from at least two independent 
reports based on the array of patient speci-
mens. Analysis of the first study [25] revealed 
that Prx1, 2 and 4 were highly expressed in 
tumors of lung adenocarcinoma and squamous 
cell carcinoma (SCC) when compared with 
those of normal lung epithelium or small/large 
cell carcinoma (Figure 1A); whereas increased 
expression of Prx3 was mainly found in tumor 
samples of lung adenocarcinoma. Analysis of 
the second study [26] revealed a very similar 
finding of increased Prxs in human lung adeno-
carcinoma and SCC, but with variations in nor-
mal lung epithelium (Figure 1B). 
To facilitate the study of Prxs in human lung 
cancer, we asked whether Prxs are differential-
ly expressed in established cell lines of human 
lung normal epithelium or various tumor types. 
Western blot was used to measure the endog-
enous protein levels of Prxs in a total of eleven 
cell lines (Figure 2A). We found that Prx1 was 
expressed in all cell lines, and the levels of Prx1 
were relatively low in normal cell lines (BEAS2B, 
NL-20 and Nuli-1), medium in cell lines of small 
cell carcinoma (H69 and H82) and relatively 
high in cell lines of lung SCC (H520, H226 and 
SKMES) and adenocarcinoma (A549, H2030 
and H2122). Moreover, Prx2 was relatively low 
Figure 2. Differential expression of 2-Cys Prxs in various cell lines and knockdown of individual Prx in human lung 
adenocarcinoma A549 cells. (A) Expression of 2-Cys Prxs in cell lines established from human lung normal epithe-
lium or different types of lung cancer. Cell lines were originally derived from: 1lung normal epithelium; 2small cell 
carcinoma; 3squamous cell carcinoma; 4adenocarcinoma; *cancer metastasis. For each cell line, cells were lysed in 
RIPA buffer at the concentration of 1× 107 cell/ml and equal volume of lysates were loaded to the gel for Western 
blot. (B-D) Knockdown of endogenous Prx1 (B), Prx3 (C) or Prx4 (D) in A549 cells using isoform specific ShRNAs 
targeting the correspondent protein coding regions. Two sets of unique ShRNA (indicated by the number in the pa-
renthesis) were used for each specified Prx target. The endogenous Prx levels were measured by Western blot from 
triplicate dishes of stable cells established by lentivrial infection and antibiotic selection. Note that knockdown of 
targeted Prx does not interfere with the expression of other isoforms of 2-Cys Prxs. 
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in normal cell lines and much higher in cell lines 
of small cell carcinoma and SCC. However, in 
some lung cancer cell lines including SKMES, 
A549 and H2030 cells, the levels of Prx2 was 
below the limit of detection or absent. On the 
other hand, Prx3 was found to be universally 
expressed in all cell lines tested at relatively 
high levels except lower expression was found 
in one of the normal cell lines (NL-20). Two of 
three normal cell lines (except Nuli-1) have rela-
tively low expression of Prx4, and higher expres-
sion of Prx4 was found in cell lines of small cell 
carcinoma, SCC (except SKMES) and adenocar-
cinoma. Taken together, these data indicate 
that there’s an overall trend of higher expres-
sion of Prx1, 2 and 4 in cell lines of small cell 
carcinoma and SCC compared with those of 
normal cell lines, whereas in lung adenocarci-
noma, the levels of Prx1 and 4 appear to be 
consistently higher than those of normal cells.  
Figure 3. Knockdown of Prx1 or Prx4 in A549 cells abolishes their ability of to form anchorage independent colo-
nies in soft agar and represses their capability of invading through matrigel. A, B: Anchorage independent colony 
formation in soft agar; C, D: Transwell cell invasion assay. Compared to wildtype parental A549 (Wt) or ShNT cells, 
*p<0.05 (n = 6, t test). 
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Knockdown of Prx1 or Prx4 in A549 cells repr- 
esses anchorage independent colony forma-
tion and matrigel invasion
 A549 cells were chosen for the following exper-
iments because there were no detectable, 
endogenous levels of Prx2 expression, which 
simplifies our efforts to characterize the contri-
bution of individual Prx in these cells. A set of 
four different ShRNA constructs targeting the 
distinctive regions of the transcript of either 
Prx1, 2 or 3, were tested for their efficiency to 
knockdown the endogenous protein expression 
by lentiviral infection. After initial evaluation of 
knockdown efficiency in HEK293T cells, we 
selected two ShRNAs that target different cod-
ing regions of either Prx1, 3 or 4 with relatively 
higher efficiency to establish stable cells in 
A549. Our efforts of establishing stable knock-
down cells were successful and we had stable 
cells completely depleted of Prx1 (Figure 2B), 
Prx3 (Figure 2C) or Prx4 (Figure 2D). Although 
2-Cys Prxs share commonly conserved 
sequences and structural motifs, our ShRNA 
knockdown was very specific in that the ShRNA 
had knockdown effect only to the targeted Prx 
but had no off-targets effects to other Prx iso-
forms. The phenotypical features of these sta-
ble cells were then compared with control cells 
expressing a non-target ShRNA (ShNT cells). 
We found that knockdown of Prx1 or Prx4 led to 
the reduction of anchorage independent colony 
Figure 4. Overexpression of Prx1 or Prx4 in A549 cells enhances their ability to form anchorage independent colo-
nies in soft agar and increase their capability of invading through matrigel. (A) The protein coding regions of human 
Prx1, Prx2, Prx3 or Prx4 gene in HEK293T cells were reverse transcribed and amplified by PCR, and then cloned 
into the pCDNA3.1-Myc vector for protein expression; (B) Myc tagged Prx1, 2, 3 or 4 expression in A549 stable cells; 
(C-F) Anchorage independent colony formation in soft agar (C, D) and transwell invasion assay (E, F) using cells with 
stably overexpression of individual Prx. 
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formation in soft agar in A549 cells (Figure 3A 
and 3B). Moreover, knockdown of Prx1 or Prx4 
also significantly repressed serum-induced cell 
invasion in matrigel invasion assay (Figure 3C 
and 3D). However, knockdown of Prx3 in A549 
cells did not produce any effects on either colo-
ny formation or cell invasion. Therefore, our 
data indicate that endogenously expressed 
Prx1 and Prx4 are required for the integrity of 
colony formation and invasion of A549 cells. 
Overexpression of Prx1 or Prx4 in A549 cells 
further enhances anchorage independent 
colony formation and matrigel invasion
Next we asked whether ectopic expression of 
Prxs in A549 cells may have an opposite effect 
on colony formation and cell invasion. The cod-
ing regions of Human Prx1~4 were amplified 
from HEK293T cells and cloned into a mamma-
lian expression vector for protein expression 
(Figure 4A). Stable cells overexpressing either 
Myc tagged Prx1, 2, 3 or 4 were established 
(Figure 4B). The phenotypical features of these 
stable cells were then compared with parental 
cells or control cells expressing an empty vec-
tor. We found that overexpression of MycPrx1 
or MycPrx4 in A549 cells led to significant 
increases in anchorage independent colony for-
mation in soft agar (Figure 4C and 4D) and cells 
invaded through matrigel (Figure 4E and 4F). 
However, overexpression of either MycPrx2 or 
MycPrx3 had no significant effects on colony 
formation in soft agar as well as cell invasion 
through matrigel. These data indicate that over-
expression of Prx1 or Prx4, but not Prx2 or 
Prx3, is able to further promote the anchorage 
independent colony formation and matrigel 
invasion of human lung cancer A549 cells. 
Prx1 and Prx4 are required for the sustained 
activation of AP-1 signaling 
To understand the molecular basis of Prx1 and 
Prx4 mediated cancer cell phenotype changes, 
we examined the global phosphokinase signal-
Figure 5. Knockdown of Prx4 represses, whereas overexpression of Prx4 activates c-Jun mediated AP-1 activation. 
(A, B) Proteome profiler human phosphokinase array (A) and quantification of phosphorylated c-Jun levels (B). -, no 
stimulation. +, serum stimulation. Compared to ShNT (+) cells, *p<0.05 (n = 4, t test). (C) Western blot of phos-
phorylated c-Jun after serum stimulation in A549 cells expressing ShNT, ShPrx4 or MycPrx4. (D) AP-1 luciferase 
reporter assay in A549 cells with or without expression of ShRNAs or MycPrxs. Compared to either ShNT or vector 
cells, *p<0.05 (n = 6, t test).
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ing changes mediated by Prx1 or Prx4 in A549 
cells. This phosphokinase assay simultaneous-
ly detected the levels of 46 phosphorylated 
proteins in duplicates, along with several pre-
designed negative and positive controls. To 
identify proteins in which phosphorylation was 
affected by the manipulation of either Prx1 or 
Prx4 levels, multiple arrays were performed 
using stable cells expressing ShNT, ShPrx1 
(ShPrx4) or MycPrx1 (MycPrx4). The following 
criteria were used to determine whether the 
phosphorylation of a particular protein was 
causally related with the levels of Prx1 or Prx4: 
(1) compared with no stimulation, the levels of 
phosphorylated protein in ShNT cells were 
induced in the presence of serum containing 
medium; (2) such induced activation was sig-
nificantly repressed in ShPrx1 and ShPrx4 cells; 
and (3) the phosphorylation can be further 
enhanced in MycPrx1 and MycPrx4 cells. 
Following this criteria, we identified that the lev-
els of phosphorylated c-Jun was positively cor-
related with the levels of Prx1 or Prx4 in A549 
cells (Figure 5A and 5B show results from 
ShPrx4/MycPrx4 cells and similar results were 
obtained from ShPrx1/MycPrx1 cells). 
To confirm whether the activation/phosphoryla-
tion of c-Jun was indeed affected by depletion 
or overexpression of Prx1 or Prx4, Western blot 
was used to examine a serum-induced, time-
dependent phosphorylation of c-Jun in these 
cells. Previous studies have shown that phos-
phorylation of Serine residues at 63 (Ser63) 
and 73 (Ser73) determines the activation of 
c-Jun, we thus examined the levels of phos-
Figure 6. Knockdown of Prx4 represses, whereas overexpression of MycPrx4 enhances tumor xenograft growth and 
metastasis formation in mouse models in vivo. (A) Tumor growth curves of subcutaneously injected A549-ShNT, 
ShPrx4 or MycPrx4 cells into SCID mice; (B, C) Images (B) and average weight (C) of primary tumors extracted from 
injection sites 40 days post subcutaneous injection; (D) Lung tumor nodules found in SCID mice receiving tail vein 
injection of A549-ShNT, ShPrx4 or MycPrx4 cells. Arrow heads indicated tumor nodules. Bar graph shows the aver-
age number of tumor nodules found in each experimental group. Compared to mice receiving ShNT cells, *p<0.05 
(n = 9, t test). 
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phorylation at both sites with phospho-specific 
antibodies. As shown in Figure 5C, ShPrx4 cells 
showed a significant reduction in the phosphor-
ylation levels of c-Jun at Ser63 and Ser73 resi-
dues at multiple time points after serum stimu-
lation, and the levels of phosphorylation at both 
residues in MycPrx4 cells were significantly 
higher than those of ShNT cells (Figure 5C). 
C-Jun is one of the major components of the 
AP-1 transcription factor complex, whose acti-
vation contributes to multiple oncogenic pro-
cesses including the stimulation of cell growth 
and proliferation, cell invasion and metastasis 
in various cancers. Therefore, we used an AP-1 
luciferase reporter assay to test whether 
manipulation of Prx1 or Prx4 levels had any 
effect on the AP-1 mediated luciferase expres-
sion. As shown in Figure 5D, depletion of either 
Prx1 or Prx4 in A549 cells led to the reduction 
of the AP-1 luciferase activity, whereas deple-
tion of Prx3 had no significant effect. Compared 
with vector control cells, overexpression of 
either MycPrx1 or MycPrx4 significantly stimu-
lated the AP-1 luciferase reporter activity, but 
overexpression of MycPrx2 or MyxPrx3 did not 
affect the AP-1 luciferase activity. Therefore, 
through maintaining and promoting the onco-
genic AP-1 activation, expression of Prx1 and 
Prx4 may contribute to the activation of AP-1 
downstream signaling pathways that are criti-
cal for the malignancy of human lung cancer 
cells. 
Prx4 expression is required for tumor xeno-
graft growth and metastasis formation in vivo 
From cell culture studies we found that both 
Prx1 and Prx4 were important for A549 cells to 
grow in soft agar and to invade through matri-
gel. Previous studies have shown that down-
regulation of Prx1 in A549 cells led to the 
reduced tumor xenograft growth and inhibition 
of metastasis in mouse xenograft experiments 
[27-29], which were consistent with our obser-
vation that knockdown of Prx1 led to reduced 
malignant phenotype in A549 cells. However, 
whether manipulating the levels of Prx4 in 
A549 cells may affect tumor growth and metas-
tasis in vivo has not been reported. Therefore, 
we injected ShNT, ShSrx or MycPrx4 cells sub-
cutaneously into groups of SCID mice to exam-
ine the ability of these cells to initiate/support 
tumor growth in vivo. Compared with mice 
injected with ShNT cells, subcutaneous tumor 
growth in mice injected with ShPrx4 cells was 
significantly reduced, whereas tumor growth in 
mice injected with MycPrx4 cells was signifi-
cantly accelerated (Figure 6A). By the end of 
the sixth week after subcutaneous injection, all 
mice were euthanized and tumors were extract-
ed from all mice, except one mouse in ShPrx4 
group was free of tumor mass (Figure 6B). 
Compared with tumors from mice receiving 
ShNT cells, tumors from mice receiving MycPrx4 
cells were much larger in size and heavier in 
weight, while tumors from mice receiving 
ShPrx4 cells were smaller in size and lighter in 
weight (Figure 6B and 6C). These data suggest 
that Prx4 positively contributes to tumor xeno-
graft growth in vivo, which is consistent with 
the observation that knockdown (or overex-
pression) of Prx4 leads to reduced (or 
enhanced) colony formation of A549 cells in 
soft agar.  
The malignancy of cancer cells can be evaluat-
ed by their invasiveness and their capability of 
initiating tumor metastasis in vivo. Based on 
the observation that Prx4 is required for A549 
cells to invade through matrigel in culture, we 
hypothesized that Prx4 is also required for lung 
cancer metastasis. To test this hypothesis, 
A549 cells expressing ShNT, ShSrx or MycPrx4 
were injected into the tail vein of SCID mice. At 
8 weeks after injection, all mice were eutha-
nized and mouse lung was extracted. Tumor 
nodules with diameter equal or larger than 1.0 
mm were identified microscopically (as indicat-
ed by the arrow heads in Figure 6D) and data 
were analyzed. Compared with mice receiving 
ShNT cells, there’s a significant reduction in the 
number of tumor nodules in mice injected with 
ShPrx4 cells; whereas a robust increase in the 
number of tumor nodules was found in mice 
injected with MycPrx4 cells (Figure 6D). 
Therefore, knockdown of Prx4 in A549 cells 
represses, whereas overexpression of MycPrx4 
enhances, their ability to form lung tumor 
metastasis in SCID mice. 
Discussion 
The Prx family of peroxidase provides critical 
defense against oxidative stress through scav-
enging H2O2 and thus protects cells from oxida-
tive damages. Therefore, the abundance of 
Prxs is normally associated with attenuation of 
oxidative stress and increased rate of cell sur-
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vival under various stress conditions. Due to an 
essential secondary messenger function of 
H2O2, Prxs are also considered as receptors for 
cellular H2O2 and thus play multiple roles in 
many physiological as well as pathological pro-
cesses (for review, refer to [30]). In human lung 
cancer, Prx1 is frequently identified as one of 
the major cellular antioxidants that are prefer-
entially expressed in cancer tissues but not in 
normal lung epithelium or nonmalignant tumors 
[13]. As a validated biomarker of lung adeno-
carcinoma [12, 31, 32],  it mediates the pro-
oxidants induced lung cancer cell growth and 
invasion [33] and is required for human lung 
cancer cells to grow as tumor xenograft and to 
establish cancer metastasis in mice [27, 29]. 
Expression of Prx1 also confers human lung 
cancer cells resistance to ionizing radiation 
[27] and chemotherapeutic drugs [34]. Similar 
to Prx1, Prx2 is also identified as aberrantly 
increased in human lung cancer and its levels 
are positively correlated with high-grade lung 
carcinomas [32, 35], but the molecular basis of 
Prx2 contribution to lung cancer development 
has not been investigated. In breast cancer, 
however, silencing of Prx2 leads to inhibition of 
cancer cell growth and reduced formation of 
lung metastasis in mice, which may be attrib-
uted to a novel function of Prx2 in regulating 
cellular metabolism [36]. Unlike Prx1 or Prx2, 
which are mainly localized in the cytosol, Prx3 
is a mitochondria protein that is also overex-
pressed in human lung cancer [37]. Disruption 
of Prx3 in mitochondria may function as a novel 
mechanism of cellular response to cancer che-
motherapeutics [38]. Prx4 is mainly localized in 
the endoplasmic reticulum and is involved in 
cellular inflammatory response [39]. However, 
the role of Prx4 in human cancer is much less 
studied compared with other 2-Cys Prxs. By 
loss- and gain-of-function experiments, our 
study reveals a critical role of Prx1 and Prx4 in 
human lung cancer pathogenesis.  
To date there are no genetic mutations identi-
fied in the Prx family of proteins that may asso-
ciate with human diseases including cancer. 
Therefore, the contribution of Prxs to human 
cancer development is mainly resulted from 
their aberrantly activated expression rather 
than any genetic gain or loss of functional 
mutations. Expression of Prxs can be regulated 
at multiple levels, in which the activation of ge- 
ne transcription plays a major role. Carcinogens 
and tumor promoters, such as cigarette smoke, 
asbestos, 4-(Methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK), phorbol acetate and arse-
nate, have been shown to stimulate the expres-
sion of 2-Cys Prxs through activation of protein 
kinase C, mitogen activated protein kinase 
(MAPK) and P38MAPK pathways [32, 40, 41]. 
Hypoxia may also have some effect on the 
expression of 2-Cys Prx expression, such as 
activation of Prx 1 [42, 43]. Among all the tran-
scription factors, nuclear related factor 2 (Nrf2) 
plays a critical role in the activation of 2-Cys Prx 
expression [30]. In our study we identified that 
the levels of Prx1 and Prx4 were much higher in 
human lung cancer cells. However, we did not 
study the mechanisms of their up-regulation, in 
the future it may be of interesting to under-
stand why Prx1 and Prx4 were aberrantly acti-
vated in human lung cancer cells. 
Due to the complicated role of H2O2 in mediat-
ing cell signaling, it is not surprising that the 
function of Prxs is beyond the simple model of 
acting as a pro-oncogenic factor. In fact, mem-
bers of the Prx family may also have tumor sup-
pressor activities. In particular, genomic loss of 
Prx1 in mice leads to spontaneous tumor for-
mation in multiple organs, which suggest that 
Prx1 may function as a tumor suppressor [19]. 
Interestingly, the effect of Prx1 depletion in 
mice may be strain dependent, since Prx1 null 
mice established from another group are com-
pletely normal and free of tumors. Other 2-Cys 
Prx null mice, including genomic knockout of 
Prx2, 3 or 4 [44-47], are also phenotypically 
normal and free of developmental defects. 
However, one of the common features of Prx 
knockout mice is that they are more sensitive 
to oxidative stress induced cell death in gener-
al. In our study we found that overexpression of 
Prx1 or Prx4 was able to further promote the 
malignancy of human lung cancer cells. Sys- 
tematic overexpression of Prx4 in mice, howev-
er, is not able to drive spontaneous tumorigen-
esis under laboratory conditions [48]. It is not 
clear whether overexpression of both Prx1 and 
Prx4 in mice is sufficient to drive de novo tumor-
igenesis in vivo. Transgenic mice that overex-
press Prx3 also develop normally, and cells 
from these mice have an increased resistance 
to stress-induced cell death [49]. In the future, 
it will be of interest to study whether overex-
pression of a single or any combination of 2-Cys 
Prx in mice may affect the process of tumori-
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genesis or malignant progression of lung tum- 
ors induced by carcinogens, tumor promoters 
or pre-existed, oncogenic mutations.  
2-Cys Prxs are also involved in the activation of 
various signaling pathways [30]. In mechanistic 
study, our data demonstrated a critical role of 
Prx1 and Prx4 in mediating the sustained acti-
vation of c-Jun, a major component of the AP-1 
transcription factor complex. The molecular 
mechanisms of why Prx1 and Prx4 are required 
for c-Jun phosphorylation and the AP-1 mediat-
ed promoter activity still remain elusive. The 
AP-1 activity is stimulated by numerous factors 
including growth factors, chemokines and envi-
ronmental stress. As a heterodimer, the AP-1 
complex contains components of c-Fos, FosB, 
FosL1 (Fra-1), FosL2 (Fra-2), c-Jun, JunB, JunD, 
etc. Among them, c-Jun is activated by the 
phosphorylation from upstream activated 
kinases including MAPK, RSK and JNK kinase 
systems [50]. Additionally, the transcriptional 
activity of AP-1 complex is also regulated by 
s-glutathionylation [51, 52], s-nitrosylation [53] 
and oxidation [54]. Ref-1 is a redox sensitive 
protein that activates the transcriptional activi-
ty of AP-1 either through a direct reduction of 
the oxidized cysteine residue of c-Jun [55, 56], 
or facilitating the nuclear translocation of thio-
redoxin [57-59]. In yeast, activation of Tpx1 
(yeast homologue of Prx I) facilitates the reduc-
tion of oxidized cysteine in PAP1 (yeast homo-
logue of c-Jun) and activates PAP1-dependent 
gene transcription [60, 61]. Other possible 
mechanisms have also been reported in the lit-
erature. For example, Prx1 may affect JNK 
activities either through regulating the levels of 
intracellular hydrogen peroxide [62], or directly 
interacting with GSTpi-JNK complex to cause 
the dissociation of JNK and subsequent activa-
tion [28]. It will be of interest to investigate 
whether these potential mechanisms are also 
applied in mammalian cells for Prx1 or Prx4 to 
activate the AP-1 activity. 
Activation of the AP-1 signaling is well docu-
mented in promoting the growth, proliferation, 
invasion and metastasis of human lung cancer 
cells [63, 64]. On one hand, activation of the 
AP-1 complex can induce the expression of 
downstream targeted genes including matrix 
metalloproteinase MMP1, MMP2, MMP3 and 
MMP9, osteonectin, autotaxin, etc [65, 66]. 
Expression of these genes promotes the 
remodeling of extracellular matrix, epithelial-
mesenchymal transition and cell invasion. On 
the other hand, the AP-1 complex can also func-
tion as transcriptional repressor to repress 
genes that function as invasion suppressors 
such as TSC-36, fibronectin, Krp1 and other 
proteins [67, 68]. In principle, the expression of 
these genes may be affected since we observed 
a reduced activation of c-Jun phosphorylation 
and an impaired AP-1 promoter activity in Prx1/
Prx4 knockdown cells. As a result, these gene 
expression changes may explain the reduced 
cell invasion in culture and metastasis forma-
tion in mice. Future understanding of how these 
gene expression patterns are affected in 
human lung cancer cells in response to differ-
ent levels of 2-Cys Prxs may be informative. 
Nevertheless, the contribution of 2-Cys Prxs to 
the AP-1 signaling pathway is unambiguously 
associated with cell invasion and metastasis of 
human lung cancer, targeting 2-Cys Prxs to 
develop novel therapeutic strategies in the 
future may provide novel thoughts for cancer 
prevention or drug discovery.  
In summary, in this study we analyzed the 
expression of 2-Cys Prxs in lung cancer, and 
examined their levels of expression in a variety 
of cell lines including human lung normal and 
cancer cell lines. We found that Prx1 and Prx4 
were preferentially expressed in cell lines est- 
ablished from human lung cancer including 
SCC and adenocarcinoma. We demonstrated 
that Prx1 and Prx4 (but not Prx3) were required 
for human lung cancer A549 cells to form soft 
agar colony and to invade through matrigel in 
culture. Knockdown of Prx1 or Prx4 significantly 
reduced the activation of c-Jun and thus 
repressed AP-1 mediated promoter activity, 
which may contribute to the changes of cancer 
cell phenotype. In mouse xenograft models in 
vivo, we found that knockdown of Prx4 reduced 
subcutaneous tumor growth and blocked 
metastasis formation. Furthermore, overex-
pression of Prx1 or Prx4 further enhanced the 
malignancy of A549 cells in culture and in 
mouse xenografts in vivo. Our data provide an 
in-depth understanding of the contribution of 
Prx1 and Prx4 to lung cancer development and 
provide valuable information for future develop-
ment of therapeutic methods that targeting 
2-Cys Prxs. 
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